How COVID-19 Treatment in Pregnancy Reflects Healthcare Utilization During a Pandemic: A Two-Stage Individual Participant Data Meta-Analysis Combining Case-Based Registries.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maisonneuve Emeline, De Bruin Odette, Favre Guillaume, Oakley Erin, Kim Jenny Yeon Hee, Farooq Fouzia, Al-Fadel Nouf, Almutairi Abdulaali, Del Mar Gil Maria, Fernandez Buhigas Irene, Visentin Silvia, Cosmi Erich, Surita Fernanda, Souza Renato T, Cecatti José G, Costa Maria Laura, Sanin-Blair Jose, Tolosa Jorge E, Hadar Eran, Goncé Anna, Poncelet Christophe, Forestier Fabienne, Quibel Thibaud, Martinez de Tejada Begoña, Eggel-Hort Béatrice, Capoccia Brugger Romina, Surbek Daniel, Raio Luigi, Radan Anda-Petronela, Todesco-Bernasconi Monya, Monod Cécile, Schäffer Leonard, Harnadi Anett, Mousavi Sayed Hamid, Ayres-de-Campos Diogo, Pomar Léo, Sichitiu Joanna, Salomon Laurent J, Ville Yves, Papadia Andrea, Rossier Marie-Claude, Schuler-Faccini Lavinia, Goncalves Pereira Natalya, Etchegaray Adolfo, Nieto-Calvache Albaro Jose, Geary Michael, Fuenzalida Javiera, Grawe Claudia, Ko Albert I, Johann Silke, De Santis Marco, Voekt Cora Alexandra, Hcini Najeh, Nielsen-Saines Karin, Garabedian Charles, Sentilhes Loïc, May Feuerschuette Otto H, Vetter Grit, Wardhana Manggala Pasca, Dajti Irida, Bloemenkamp Kitty W M, Siiskonen Satu J, Smith Emily R, Baud David, Panchaud Alice, Sturkenboom Miriam C J M
Аннотация
METHODS: We conducted a two-stage individual participant data meta-analysis of proportions from primary data on medications used to treat COVID-19 during pregnancy. A common data model was developed to pool the data from single-country and international registries. Data from pregnant individuals with COVID-19 between February 2020 and October 2022 were included in study platforms across 9 data sources. Patient information was abstracted from medical records.
RESULTS: Among 24 937 pregnant individuals, the pooled prevalences of individuals receiving medications to treat COVID-19 were: 34.7% heparin, 9.8% antibiotics, 4.9% corticosteroids, 2.2% antivirals, 0.8% antimalarials, 0.3% convalescent plasma, 0.2% immunosuppressants, and 0.02% monoclonal antibodies. Prevalence of medication use was higher in hospitalized individuals than in non-hospitalized individuals: 58.4% versus 17.9% for heparin, 26.9% versus 5.7% for antibiotics, 17.5% versus 1.3% for corticosteroids, 10.3% versus 0.3% for antivirals, and 4.5% versus 0.1% for antimalarials. The prevalence of corticosteroid use was lower in the first trimester (0.1%) compared with the second (7.2%) and third (4.9%) trimesters of pregnancy. The prevalence of medications differed widely across countries.
CONCLUSION: Medication to treat COVID-19 was more frequently used in pregnant individuals hospitalized for COVID-19. Corticosteroids were used less in the first trimester of pregnancy. The differences in use between countries could reflect differences in the clinical management and access to medications for this population at risk of severe disease.